Sign in
SER Stock Price, Chart, Stats & News
Serina Therapeutics, Inc.
Save
Serina Therapeutics, Inc. (SER) does not currently pay a dividend.
–
Market cap
–
Current P/E
–
Forward P/E
SER chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 43.85% |
Operating margin | -18478.46% |
Pretax margin | -14766.92% |
Net margin | -14950.77% |
Effective tax rate | -0.09% |
ROA | -279.61% |
ROE | -1487.64% |
D/E | -5.30x |
Interest coverage ratio | -112.78x |
SER valuation
P/E | – |
P/S | 174.62x |
P/B | -625.17x |
P/CF | -1.29x |
P/FCF | -1.26x |
P/OCF | -1.29x |
PEG | 0.75x |
EV multiple | -1.16x |
About
Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy.
Similar securities
Based on sector and market capitalization
Report issue